



Rodabe Amaria, MD

Director, Clinical Research within Melanoma Medical Oncology

MD Anderson Cancer Center.

TIL Therapy in Melanoma

Since joining the Department of Melanoma Medical Oncology at MD Anderson Cancer Center in July 2013, Dr. Amaria has worked to establish herself as a clinical and translational researcher. She has been the Principal Investigator of numerous clinical trials including a mix of industry-sponsored trials and investigator-initiated where she had the key role in design and implementation. Dr. Amaria's research interests have coalesced around three major subjects; neoadjuvant therapy, trials for NRAS mutated melanoma and adoptive cell therapy in metastatic melanoma. Dr Amaria leads the MD Anderson Adoptive Cell Therapy with Tumor Infiltrating Lymphocyte (TIL) program and has extensive experience designing and implementing studies using both un-engineered and engineered TIL. She is also managing TIL therapy in other solid tumors including various forms of gynecologic and gastrointestinal cancers and sarcomas. She is also the leader of the MD Anderson Standard of Care TIL Therapy program and has been instrumental in designing workflows to support standard of care TIL. Additionally, Dr. Amaria has established a busy clinical practice and has extensive experience treating melanoma patients on and off clinical trial protocols. She is also the Director of Clinical Research within Melanoma Medical Oncology at MD Anderson Cancer Center.